Impact of muscle loss on chemotherapy side effects in cancer patients
Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments. Prospective Cohort Study
This study is testing how muscle loss affects the side effects of chemotherapy in cancer patients to see if it makes treatment harder to handle.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Metropole Savoie Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chambéry) |
| Trial ID | NCT06274268 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to investigate how sarcopenia, or muscle loss, affects the occurrence of treatment-related toxicity during the initial phase of chemotherapy in cancer patients. The study will assess participants' body composition and muscular performance through various tests, including impedancemetry and physical performance evaluations. Data will be collected at multiple points: during the first chemotherapy session, after the second course, and at 6 and 12 months post-treatment. An exploratory component will also focus on patients undergoing specific breast cancer treatments.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with a histologically confirmed solid malignant tumor requiring systemic treatment.
Not a fit: Patients with cancers not requiring systemic treatment or those with a history of cancer in the past five years may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify patients at higher risk for chemotherapy-related toxicity, allowing for tailored treatment approaches.
How similar studies have performed: While the specific approach of this study may be novel, similar studies have indicated that sarcopenia can influence treatment outcomes in cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years old * Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment. * CT/PET performed within 45 days before initiation of systemic treatment. * Patient able to sign informed consent for participation in the study * Patient affiliated to a social security system Exclusion Criteria: * History of cancer in the five years preceding inclusion other than localized skin or cervical cancers. * Patient with cancer not requiring systemic treatment. * Pregnant women. * Patient with a pace maker or defibrillator * Patient deprived of liberty or benefiting from a legal protection measure
Where this trial is running
Chambéry
- Centre Hospitalier Metropole Savoie — Chambéry, France (Recruiting)
Study contacts
- Principal investigator: Aurelie FILLON — Centre Hospitalier Metropole Savoie
- Study coordinator: Aurelie FILLON
- Email: aurelie.fillon@ch-metropole-savoie.fr
- Phone: 04.79.96.58.13
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.